Agustin Cabrera Santamaria, MD
Cardiovascular Disease · Amarillo, TXNPI 1215903265
Payments from drug & device makers
Across 631 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abiomed$2K
- Amgen$1K
- Amarin Pharma, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Boston Scientific$1K
- plus $6K from 24 others
What the payments were for
- Travel & lodging$2,46816%
- Food & beverage$12,88583%
- Education$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $2,768 |
| Abiomed | 46 | $2,118 |
| Amgen | 102 | $1,453 |
| Amarin Pharma, Inc. | 79 | $1,416 |
| E.r. Squibb & Sons, L.L.C. | 94 | $1,145 |
| Boston Scientific | 10 | $1,058 |
| Abbott | 23 | $909 |
| Pfizer | 47 | $711 |
| Johnson & Johnson | 47 | $685 |
| Novartis | 31 | $638 |
| AstraZeneca | 27 | $526 |
| Boehringer Ingelheim | 16 | $469 |
| Arbor Pharmaceuticals, Inc. | 18 | $246 |
| Kowa Pharmaceuticals America, Inc. | 29 | $234 |
| Biotronik Inc. | 3 | $188 |
| Teleflex LLC | 1 | $150 |
| Novo Nordisk | 8 | $146 |
| Merck | 8 | $123 |
| Bayer | 6 | $116 |
| Medicure Pharma Inc. | 2 | $103 |
| Gilead | 3 | $57 |
| Tactile Systems Technology Inc | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Itamar Medical Inc | 1 | $25 |
| Angiodynamics, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Advisa$1,177
- Impella$823
- Varithena Administration Pack$647
- Micra$334
- JARDIANCE$226
- Catheter - GuideLiner$150
- Acticor 7 VR-T DX$141
- BioMonitor$141
- Edora 8 DR-T$141
- Rivacor 7 DR-T$141
- Perclose ProGlide suture mediated closure system$126
- Vascepa$125
- CAMZYOS$125
- SYMPLICITY G3$124
- Repatha$123
- VYNDAQEL$110
- CardioMEMS HF System$110
- JETi All In One Non-Sterile Kit$110
How this compares
$15,532 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 360 | $398,648 |
| XareltoRivaroxaban | 374 | $385,793 |
| EntrestoSacubitril/Valsartan | 188 | $244,293 |
| JardianceEmpagliflozin | 121 | $170,667 |
| Repatha SureclickEvolocumab | 113 | $107,013 |
| FarxigaDapagliflozin Propanediol | 37 | $51,271 |
| VascepaIcosapent Ethyl | 62 | $41,212 |
| MultaqDronedarone Hcl | 14 | $15,208 |
| Metoprolol Succinate | 1,127 | $12,493 |
| Ranolazine ErRanolazine | 144 | $12,462 |
| Rosuvastatin Calcium | 713 | $9,028 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 696 | $8,467 |
| Losartan Potassium | 900 | $8,298 |
| Atorvastatin Calcium | 947 | $7,982 |
| Ezetimibe | 184 | $5,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $711 | $398,648360 claims |
| Johnson & JohnsonXarelto | $685 | $385,793374 claims |
| NovartisEntresto | $638 | $244,293188 claims |
| Boehringer IngelheimJardiance | $469 | $170,667121 claims |
| AstraZenecaFarxiga | $526 | $51,27137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Amarillo
- David BrabhamAmarillo$11.5M
- Alfred ChuAmarillo$1.3M
- Joaquin Martinez Arraras CaroAmarillo$1.2M
- Rajesh NambiarAmarillo$574K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.